Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy

Chiappini, Elena; Galli, Luisa; Tovo, Pier-Angelo; Gabiano, Clara; Lisi, Catiuscia; Bernardi, Stefania; Viganò, Alessandra; Guarino, Alfredo; Giaquinto, Carlo; Esposito, Susanna; Badolato, Raffaele; Di Bari, Cesare; Rosso, Raffaella; Genovese, Orazio; Masi, Massimo; Mazza, Antonio; de Martino, Maurizio

doi:10.1186/1471-2334-9-140

Table 1 Characteristics of 40 perinatal HIV-infected children receiving HAART before 6 months of age.

From: Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy

CDC category	Age at first HAART (years)	First HAART Regimen	Age at first regimen discontinuation (years)	Reason for discontinuation	Age at last follow-up (years)	CD4 ⁺ T cells at last follow up (%)	Viral load at last follow-up (Log ₁₀ copies/mL)
B1	0.21	DDI+D4T+LPV/r	6.40	Simplification	9.83	42	<1.69
A1	0.18	3TC+D4T+ LPV/r	6.65	Simplification	8.87	28	1.85
B1	0.26	AZT+3TC+NFV	Ongoing		8.67	38	<1.69
B2	0.48	AZT+3TC+NFV	Ongoing		8.66	37	3.00
A1	0.27	3TC+D4T+NFV	5.00	Simplification	8.75	45	<1.69
A2	0.08	3TC+D4T+NFV	Ongoing		8.81	35	<1.69
B1	0.30	AZT+3TC+NFV	4.47	Simplification	8.03	35	<1.69
A1	0.33	ABC+3TC+NFV	7.17	Virologic failure	7.70	28	2.63
A2	0.44	AZT+3TC+NFV	Ongoing		8.32	33	<1.69
N1	0.34	AZT+3TC+NVP	3.89	Therapy interruption	5.43	38	3.73
A2	0.34	3TC+D4T+NFV	Ongoing		6.94	37	<1.69
A1	0.33	AZT+3TC+NFV	1.50	Therapy interruption	7.41	31	5.10
A1	0.39	DDI+D4T+NFV	5.71	Simplification	7.28	32	4.00
N1	0.21	DDI+D4T+NFV	Ongoing		7.11	30	<1.69
A1	0.34	AZT+3TC+NFV	4.58	Simplification	7.78	44	<1.69
N2	0.13	3TC+D4T+NVP	Ongoing		6.40	44	<1.69
A2	0.28	AZT+3TC+NFV	Ongoing		6.08	25	<1.69
A1	0.30	3TC+D4T+NFV	6.21	Simplification	6.28	43	<1.69
A2	0.18	DDI+D4T+NFV	3.50	Virologic failure	6.03	39	<1.69
B1	0.36	3TC+D4T+NFV	Ongoing		6.24	38	<1.69
A2	0.19	DDI+D4T+NFV	1.64	Therapy interruption	6.56	20	<1.69
N1	0.25	AZT+3TC+NVP	Ongoing		5.19	42	<1.69
N1	0.42	3TC+D4T+NFV	1.71	Virologic failure	4.39	39	<1.69
A1	0.32	3TC+D4T+NFV	4.30	Simplification	5.04	37	<1.69
N1	0.27	AZT+3TC+NFV	3.21	Simplification	5.15	43	<1.69
N1	0.22	3TC+D4T+NFV	Ongoing		4.66	32	<1.69
A1	0.48	AZT+3TC+NVP	Ongoing		5.56	34	<1.69
A1	0.45	AZT+3TC+NFV	2.34	Virologic failure	5.88	39	<1.69
B2	0.15	ABC+D4T+NVP	Ongoing		4.18	32	<1.69
B1	0.45	3TC+D4T+NFV	2.78	Virologic failure	5.06	28	2.34
B2	0.22	3TC+D4T+ LPV/r	3.77	Virologic failure	5.10	38	<1.69
A2	0.14	AZT+3TC+NVP	Ongoing		2.02	51	<1.69
B1	0.43	AZT+3TC+NVP	Ongoing		3.89	36	<1.69
N1	0.31	3TC+D4T+NFV	Ongoing		2.27	35	2.50
B1	0.24	3TC+D4T+NFV	1.69	Virologic failure	3.83	32	<1.69
N1	0.31	AZT+3TC+NFV	Ongoing		0.59	33	2.96
N2	0.25	AZT+3TC+NFV	2.92	Virologic failure	3.41	33	<1.69
N1	0.17	AZT+3TC+NFV	Ongoing		2.18	35	<1.69
B1	0.36	ABC+3TC+LPV/r	0.45	Liver toxicity	2.10	42	<1.69
A1	0.23	3TC+D4T+NFV	Ongoing		0.88	35	<1.69

Note: ZDV, zidovudine; 3TC, lamivudine; D4T, stavudine; DDI, didanosine; NELF, nelfinavir; LPV/r, lopinavir/ritonavir; NEV, nevirapine; ABC: abacavir.

Back to article page

ISSN: 1471-2334

Contact us

Submission enquiries: bmcinfectiousdiseases@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Infectious Diseases

Contact us